Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS5C0K
|
|||
| Drug Name |
BT5528
|
|||
| Drug Type |
Bicycle?toxin conjugate
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
Bicycle Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ephrin type-A receptor 2 (EPHA2) | Target Info | . | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Axon guidance | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | EphrinA-EPHA pathway | |||
| Arf6 signaling events | ||||
| Direct p53 effectors | ||||
| EPHA forward signaling | ||||
| Stabilization and expansion of the E-cadherin adherens junction | ||||
| EPHA2 forward signaling | ||||
| Reactome | EPH-Ephrin signaling | |||
| EPHA-mediated growth cone collapse | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04180371) Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression. U.S. National Institutes of Health. | |||
| REF 2 | MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.